Case Reports in Ophthalmology, 2022 We describe the clinical features and treatment outcome of a patient with combined central retinal vein occlusion and cilioretinal artery occlusion. A 52-year-old female presented to our clinic with decreased vision in the right eye for 4 days.
Alemu Kerie Tesfaw +2 more
doaj +1 more source
Retrospective, controlled observational case study of patients with central retinal vein occlusion and initially low visual acuity treated with an intravitreal dexamethasone implant [PDF]
, 2016 Background Patients with initially low visual acuity were excluded from the therapy approval studies for retinal vein occlusion. But up to 28 % of patients presenting with central retinal vein occlusion have a baseline BCVA of less than 34 ETDRS letters (
Annabelle Eckert +9 more
core +2 more sources
Comparison between “early” or “late” intravitreal injection of dexamethasone implant in branch (BRVO) or central (CRVO) retinal vein occlusion: six months follow-up [PDF]
, 2017 AIM: The aim of this study was to compare early and late injections of intravitreal dexamethasone implant in patients affected by central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO) with a six-months follow-up.
AUTOLITANO, MONICA +6 more
core +1 more source
Central retinal vein occlusion associated with platelet activation
Therapeutic Advances in Ophthalmology, 2019 Purpose: The aim of this article is to determine and compare the platelet activation by three main platelet activation parameters: mean platelet volume, platelet distribution width, and plateletcrit in patients with central retinal vein occlusion and ...
Mehmet Citirik
doaj +1 more source
Comparison of Intravitreal Bevacizumab Upload Followed by a Dexamethasone Implant versus Dexamethasone Implant Monotherapy for Retinal Vein Occlusion with Macular Edema [PDF]
, 2012 Purpose: To compare the efficacy and safety of three intravitreal bevacizumab upload injections followed by a dexamethasone implant versus dexamethasone implant monotherapy in eyes with macular edema due to retinal vein occlusion.
Haritoglou, Christos +7 more
core +1 more source
Risk Factors for Central and Branch Retinal Vein Occlusion: A Meta-Analysis of Published Clinical Data [PDF]
, 2014 Retinal vein occlusion (RVO) is a major cause of vision loss. Of the two main types of RVO, branch retinal vein occlusion (BRVO) is 4 to 6 times more prevalent than central retinal vein occlusion (CRVO).
Kolář Petr
core +4 more sources
Adverse events associated with intraocular injection of anti-VEGF(bevacizumab) in retinal vein ccclusion: a case report [PDF]
, 2015 Introduction: Antiangiogenic agents are often administered for treatment of Branch Retinal Vein Occlusion (BRVO). Among them, Bevacizumab has noticeable antiangiogenic and antiedemigenic properties and possesses great capacity to penetrate the retinal ...
ARTICO, Marco +7 more
core +1 more source
Ocriplasmin in the treatment of vitreomacular traction in a patient with central retinal vein occlusion. a case report [PDF]
, 2018 Aim: To investigate the efficacy of intravitreal injection of ocriplasmin (JETREA®) in the treat-ment of vitreomacular traction (VMT). Materials and Methods: An 81-year-old man with VMT associated with central retinal vein occlusion in his left eye, was ...
Antonio Esposito, Raffaele +3 more
core +2 more sources
Alʹmanah Kliničeskoj Mediciny, 2016 Aim: To assess medical and social issues of occupational rehabilitation in elderly patients with vascular eye diseases. Materials and methods: The results of examination of 572 patients and disabled persons after acute occlusion of central retinal artery,
A. M. Razumovskaya +2 more
doaj +1 more source
Integrated results from the COPERNICUS and GALILEO studies. [PDF]
, 2017 OBJECTIVES: To report on the efficacy and safety of intravitreal aflibercept in patients with macular edema secondary to central retinal vein occlusion (CRVO) in an integrated analysis of COPERNICUS and GALILEO.
Ahlers, Christiane +13 more
core +3 more sources